Regen BioPharma Inc (RGBP) Form 8-K — Nov 2, 2026
Regen Biopharma entered a securities purchase agreement with Coventry Enterprises on October 27, 2026 for a $125,000 10% unsecured promissory note. Coventry retained $12,500 via original issue discount, leaving $112,500 in net proceeds, of which $71,557 satisfied existing convertible debt, and the Company must make 8 monthly payments of $17,187.50 starting six months after funding. The note is convertible upon default into common stock at 90% of the lowest trading price over the prior 20 days — a heavily dilutive default-conversion feature.
Key figures
- Debt Amount
- 125000
- Interest Rate
- 0.1
- Shares Outstanding
- 2029228670
- Note term months
- 18
- Max single drawdown
- 250000
- Equity line commitment
- 10000000
- Share reserve for note
- 731816
- Equity line term months
- 36
- Existing debt satisfied
- 71557
- Original issue discount
- 12500
- Beneficial ownership cap
- 4.99%
- Guaranteed interest total
- 12500
- Payments begin months after funding
- 6
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.